Global Cushing's Disease Treatment Market Size By Type (Type I, Type II), By Application (Application I, Application II), By Region, And Segment Forecasts, 2023 to 2032

The Global Cushing’s Disease Treatment Market was valued at USD 1.3 billion in 2023 and is projected to surpass USD 2.6 billion by 2031, growing at a CAGR of 9.3% during the forecast period (2023–2031). The market is driven by increasing prevalence of pituitary tumors, rising awareness and early diagnosis of endocrine disorders, and the growing demand for targeted pharmacological therapies. Cushing’s disease, a rare condition caused by excessive adrenocorticotropic hormone (ACTH) production, often leads to severe metabolic complications. With advancements in diagnostic tools and the development of novel drug therapies such as steroidogenesis inhibitors and glucocorticoid receptor antagonists, the treatment landscape is rapidly evolving.

Drivers:

1. Rising Prevalence of Pituitary Disorders:

The increasing incidence of ACTH-secreting pituitary adenomas, a major cause of Cushing’s disease, is significantly driving treatment demand. Improvements in diagnostic imaging and endocrinological evaluations are contributing to higher detection rates.

2. Advancements in Drug Therapies:

Pharmaceutical innovations, including next-generation steroidogenesis inhibitors and peptide receptor antagonists, are offering effective alternatives to surgical interventions, particularly for recurrent or inoperable cases.

3. Growing Awareness and Early Diagnosis:

Awareness campaigns and educational initiatives have improved the recognition of symptoms such as obesity, hypertension, and osteoporosis, leading to earlier diagnosis and intervention.

Restraints:

1. High Treatment Costs and Limited Access:

Targeted therapies and hormonal modulators often come at a premium, limiting access in low-income regions and affecting patient adherence to long-term treatment regimens.

2. Post-Surgical Complications and Disease Recurrence:

While transsphenoidal surgery remains the first-line treatment, postoperative complications and disease recurrence present clinical challenges, highlighting the need for long-term medical therapies.

Opportunity:

1. Expansion of Non-Invasive Treatment Options:

The rise of non-surgical therapeutic approaches, including oral medications and depot injections, is enabling personalized care and expanding the market’s reach among non-surgical candidates.

2. Emerging Markets and Healthcare Investments:

Rising healthcare spending and infrastructure improvements in Latin America, Asia-Pacific, and the Middle East are opening new avenues for diagnosis and treatment of rare endocrine diseases.

Market by System Type Insights:

By treatment type, the Steroidogenesis Inhibitors segment accounted for the largest share in 2023, owing to its efficacy in reducing cortisol levels in patients who are ineligible for surgery or have residual disease post-operation. Key drugs such as ketoconazole and osilodrostat have become mainstays in chronic disease management.

Meanwhile, Glucocorticoid Receptor Antagonists are gaining traction as a second-line option, especially in cases where metabolic disturbances persist despite cortisol suppression.

Market by End-Use Insights:

In terms of end use, Hospitals and Specialty Clinics dominated the market in 2023, driven by the availability of advanced diagnostic and surgical infrastructure. These settings are typically preferred for the initial diagnosis, surgery, and multidisciplinary management of Cushing’s disease.

Homecare Settings are expected to see growing demand, particularly due to the increasing availability of oral therapies and patient support programs that facilitate long-term disease monitoring outside hospital environments.

Market by Regional Insights:

North America held the largest share of the global Cushing’s disease treatment market in 2023, fueled by strong healthcare infrastructure, favorable reimbursement policies, and early adoption of novel therapies.

Europe follows closely, driven by robust clinical research activity and government-supported rare disease programs.

Asia-Pacific is anticipated to witness the highest CAGR during the forecast period, supported by increasing disease awareness, improving access to diagnostics, and expanding pharmaceutical markets in China, India, and Japan.

Competitive Scenario:

Key players in the global Cushing’s disease treatment market include:

Recordati S.p.A.

Novartis AG

Corcept Therapeutics

HRA Pharma

Strongbridge Biopharma plc

Millendo Therapeutics

Crinetics Pharmaceuticals

These companies are actively involved in clinical trials, FDA approvals, and global expansion to meet the growing demand for effective treatment modalities. Recent developments include:

2023: Recordati gained expanded EU approval for Isturisa (osilodrostat) as a first-line treatment for adults with Cushing’s disease.

2024: Corcept Therapeutics announced positive Phase III results for relacorilant, a selective glucocorticoid receptor modulator.

2025: Crinetics Pharmaceuticals initiated pivotal studies for paltusotine, a once-daily oral treatment under investigation for ACTH-dependent Cushing’s disease.

Scope of Work – Global Cushing’s Disease Treatment Market

Report Metric Details

Market Size (2023) USD 1.3 billion

Projected Market Size (2031) USD 2.6 billion

CAGR (2023–2031) 9.3%

Market Segments By Treatment Type (Steroidogenesis Inhibitors, GR Antagonists), By End-Use (Hospitals, Specialty Clinics, Homecare Settings), By Region

Growth Drivers Increasing prevalence of pituitary tumors, advancements in targeted therapies, rising awareness of endocrine disorders

Opportunities Expansion in emerging markets, shift toward non-invasive and oral therapies

Key Market Developments:

Recordati S.p.A. received marketing authorization in multiple APAC countries for osilodrostat in 2024.

Corcept Therapeutics expanded its global distribution network for Korlym in Latin America and Southeast Asia.

HRA Pharma strengthened its clinical pipeline with new formulations targeting pediatric and adolescent patients.

FAQs:

1) What is the current market size of the Global Cushing’s Disease Treatment Market?

The market was valued at USD 1.3 billion in 2023.

2) What is the major growth driver of the Global Cushing’s Disease Treatment Market?

The major growth driver is the increasing prevalence of ACTH-secreting pituitary adenomas and advances in drug therapies.

3) Which is the largest region during the forecast period in the Global Cushing’s Disease Treatment Market?

North America is projected to remain the largest regional market due to high awareness, infrastructure, and access to therapies.

4) Which segment accounted for the largest market share in the Global Cushing’s Disease Treatment Market?

The Steroidogenesis Inhibitors segment led the market in 2023.

5) Who are the key market players in the Global Cushing’s Disease Treatment Market?

Key players include Recordati S.p.A., Novartis AG, Corcept Therapeutics, HRA Pharma, and Crinetics Pharmaceuticals.